These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 33347822)

  • 21. PD-1/PD-L1-dependent immune response in colorectal cancer.
    Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
    J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab.
    Das S; Allen A; Berlin J
    Clin Colorectal Cancer; 2020 Jun; 19(2):137-140. PubMed ID: 32146081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
    Lin A; Zhang J; Luo P
    Front Immunol; 2020; 11():2039. PubMed ID: 32903444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy in colorectal cancer.
    Agarwal P; Le DT; Boland PM
    Adv Cancer Res; 2021; 151():137-196. PubMed ID: 34148613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer.
    Chen Y; Zheng X; Wu C
    Front Immunol; 2021; 12():792691. PubMed ID: 34925375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer.
    Yang Z; Wu G; Zhang X; Gao J; Meng C; Liu Y; Wei Q; Sun L; Wei P; Bai Z; Yao H; Zhang Z
    Front Immunol; 2022; 13():1001444. PubMed ID: 36159842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune checkpoint inhibitor therapy in neoadjuvant and adjuvant treatment for cancer: A paradigm shift in the treatment of resectable gastrointestinal cancer 3)A paradigm shift in the treatment of colorectal cancer.
    Oshima K; Yamazaki K
    Int J Clin Oncol; 2023 Nov; 28(11):1442-1450. PubMed ID: 37668816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial.
    Coutzac C; Bibeau F; Ben Abdelghani M; Aparicio T; Cohen R; Coquan E; Dubreuil O; Evesque L; Ghiringhelli F; Kim S; Lesourd S; Neuzillet C; Phelip JM; Piessen G; Rochigneux P; Samalin E; Soularue E; Touchefeu Y; Tougeron D; Zaanan A; de la Fouchardière C
    Dig Liver Dis; 2022 Oct; 54(10):1335-1341. PubMed ID: 35907691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer.
    Zhou L; Yang XQ; Zhao GY; Wang FJ; Liu X
    Front Immunol; 2023; 14():1044353. PubMed ID: 36776899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transforming the landscape of colorectal cancer treatment with immunotherapy: Evolution and future horizons.
    Clerick J; Van Oosterwyck A; Carton S
    Cancer Treat Res Commun; 2024; 39():100807. PubMed ID: 38461691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches.
    Franke AJ; Skelton WP; Starr JS; Parekh H; Lee JJ; Overman MJ; Allegra C; George TJ
    J Natl Cancer Inst; 2019 Nov; 111(11):1131-1141. PubMed ID: 31322663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perioperative immune checkpoint inhibition for colorectal cancer: recent advances and future directions.
    Chen JT; Zhou YW; Han TR; Wei JL; Qiu M
    Front Immunol; 2023; 14():1269341. PubMed ID: 38022667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell-based immunotherapy approaches for colorectal cancer: main achievements and challenges.
    Shahnazari M; Samadi P; Pourjafar M; Jalali A
    Future Oncol; 2021 Aug; 17(24):3253-3270. PubMed ID: 34156258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update on the use of immunotherapy in patients with colorectal cancer.
    Nguyen M; Tipping Smith S; Lam M; Liow E; Davies A; Prenen H; Segelov E
    Expert Rev Gastroenterol Hepatol; 2021 Mar; 15(3):291-304. PubMed ID: 33138649
    [No Abstract]   [Full Text] [Related]  

  • 36. Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer.
    Yu I; Dakwar A; Takabe K
    Cells; 2023 Jan; 12(2):. PubMed ID: 36672193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management.
    Overman MJ; Ernstoff MS; Morse MA
    Am Soc Clin Oncol Educ Book; 2018 May; 38():239-247. PubMed ID: 30231358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results and challenges of immune checkpoint inhibitors in colorectal cancer.
    Emambux S; Tachon G; Junca A; Tougeron D
    Expert Opin Biol Ther; 2018 May; 18(5):561-573. PubMed ID: 29471676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategic enhancement of immune checkpoint inhibition in refractory Colorectal Cancer: Trends and future prospective.
    Liu N; Shan F; Ma M
    Int Immunopharmacol; 2021 Oct; 99():108017. PubMed ID: 34352568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant Immunotherapy in Microsatellite-Instability High Nonmetastatic Colorectal Cancer: A Single-institute Experience and Review of the Literature.
    Kinney RE; Khalil M
    Clin Colorectal Cancer; 2021 Jun; 20(2):e109-e112. PubMed ID: 33722513
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.